

## China's Borui Biomedical imitates Gilead's Coronavirus drug

14 February 2020 | News | By Ayesha Siddiqui

**The firm has successfully developed and synthesized the technology and preparations for the drug synthesis of Redidevir technology**



Borui Bio-Pharmaceutical (Suzhou) Co., Ltd. announced that it has successfully developed and synthesizes the technology and preparations for the drug synthesis of Redidevir technology. The company has produced Radixivir bulk drugs, and batch production of Radixivir preparations is in progress.

Redesivir is developed by American Gilead Company for the prevention and treatment of Ebola virus infection. It has passed Phase I and Phase II clinical trials abroad. At present, Redesivir is used for new coronavirus (2019-nCoV) infection. Phase III clinical trials are not over, so there is significant uncertainty about whether the drug will be effective against new coronavirus (2019-nCoV) infections. If the relevant clinical trial results are not satisfactory, Radesivir's imitation technology will have no significant value.

If the epidemic caused by the new coronavirus (2019-nCoV) infection is quickly controlled and relieved in the short term, the number of confirmed patients will continue to decrease, even if Redecive is approved for registration for the treatment of new coronavirus (2019-nCoV) infection, It is not expected to be a major help in combating the outbreak.

Even if the successful clinical trial of Radixivir for a new coronavirus (2019-nCoV) infection is successful, the company's aforementioned research and development will eventually be transformed into a product and put on the market. There are many uncertainties in this process, such as drug approval.

The company regards the imitation research and development of Redecive as its own social responsibility. If the product can be approved for marketing, it will be supplied to relevant patients mainly through donations during the epidemic. Therefore, considering production costs, pricing, sales volume and other aspects, the product is not expected to have a significant impact on the company's operating performance in 2020.

Recently, the company has completed the research and development of Radixivir imitation technology, and mass produced Radixivir. The company will continue to pay attention to the results of Phase III clinical trials of Radixivir, and will carry out follow-up work in a timely manner in accordance with national and social needs.

The company regards the imitation research and development of Redecive as its social responsibility. If the product can be approved for marketing, it will be supplied to relevant patients mainly through donations during the epidemic. Therefore, considering production costs, pricing, sales volume and other aspects, the product is not expected to have a significant impact on the company's operating performance in 2020.